Asthika Goonewardene
Stock Analyst at Truist Financial
(3.84)
# 1,968
Out of 4,792 analysts
321
Total ratings
45.5%
Success rate
5.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Reiterated: Buy | $32 → $45 | $28.58 | +57.48% | 6 | Aug 13, 2026 | |
| ACET Adicet Bio | Reiterated: Buy | n/a | $9.47 | - | 14 | Mar 16, 2026 | |
| ALLO Allogene Therapeutics | Reiterated: Buy | $10 | $1.76 | +468.18% | 20 | Mar 13, 2026 | |
| BNTX BioNTech SE | Reiterated: Buy | $155 | $97.90 | +58.32% | 19 | Mar 13, 2026 | |
| LEGN Legend Biotech | Reiterated: Buy | $70 | $19.25 | +263.73% | 10 | Mar 13, 2026 | |
| CRBU Caribou Biosciences | Reiterated: Buy | $7 | $1.36 | +416.61% | 11 | Mar 9, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | n/a | $202.50 | - | 9 | Mar 9, 2026 | |
| CGEN Compugen | Reiterated: Buy | $4 | $2.45 | +63.27% | 20 | Mar 3, 2026 | |
| ZYME Zymeworks | Reiterated: Buy | $40 | $26.93 | +48.53% | 4 | Mar 3, 2026 | |
| SEPN Septerna | Reiterated: Buy | n/a | $38.91 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $25.63 | +17.05% | 22 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $32.62 | +47.15% | 40 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $8.14 | - | 28 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $17.48 | +100.23% | 19 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $51 | $55.57 | -8.22% | 30 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.91 | +319.95% | 25 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $17.87 | - | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $127 → $145 | $144.36 | +0.44% | 12 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $230.32 | n/a | 1 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.32 | n/a | 4 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.42 | n/a | 6 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $15 | $7.54 | n/a | 3 | Aug 23, 2022 |
ArriVent BioPharma
Aug 13, 2026
Reiterated: Buy
Price Target: $32 → $45
Current: $28.58
Upside: +57.48%
Adicet Bio
Mar 16, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.47
Upside: -
Allogene Therapeutics
Mar 13, 2026
Reiterated: Buy
Price Target: $10
Current: $1.76
Upside: +468.18%
BioNTech SE
Mar 13, 2026
Reiterated: Buy
Price Target: $155
Current: $97.90
Upside: +58.32%
Legend Biotech
Mar 13, 2026
Reiterated: Buy
Price Target: $70
Current: $19.25
Upside: +263.73%
Caribou Biosciences
Mar 9, 2026
Reiterated: Buy
Price Target: $7
Current: $1.36
Upside: +416.61%
Revolution Medicines
Mar 9, 2026
Reiterated: Buy
Price Target: n/a
Current: $202.50
Upside: -
Compugen
Mar 3, 2026
Reiterated: Buy
Price Target: $4
Current: $2.45
Upside: +63.27%
Zymeworks
Mar 3, 2026
Reiterated: Buy
Price Target: $40
Current: $26.93
Upside: +48.53%
Septerna
Mar 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $38.91
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $30
Current: $25.63
Upside: +17.05%
Feb 25, 2026
Reiterated: Buy
Price Target: $48
Current: $32.62
Upside: +47.15%
Feb 25, 2026
Reiterated: Hold
Price Target: n/a
Current: $8.14
Upside: -
Feb 24, 2026
Reiterated: Buy
Price Target: $35
Current: $17.48
Upside: +100.23%
Jan 14, 2026
Reiterated: Buy
Price Target: $51
Current: $55.57
Upside: -8.22%
Jan 13, 2026
Reiterated: Buy
Price Target: $10 → $8
Current: $1.91
Upside: +319.95%
Nov 11, 2025
Reiterated: Buy
Price Target: n/a
Current: $17.87
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $127 → $145
Current: $144.36
Upside: +0.44%
Apr 24, 2024
Reiterated: Hold
Price Target: n/a
Current: $230.32
Upside: n/a
Mar 21, 2024
Rated: Hold
Price Target: n/a
Current: $7.32
Upside: n/a
Jan 16, 2024
Rated: Hold
Price Target: n/a
Current: $1.42
Upside: n/a
Aug 23, 2022
Reiterated: Buy
Price Target: $19 → $15
Current: $7.54
Upside: n/a